<DOC>
	<DOCNO>NCT02735798</DOCNO>
	<brief_summary>This single arm pilot study 64Cu-MM-302 unlabeled MM-302 combination trastuzumab 10 patient advanced HER2+ cancer new progressive brain metastasis . Patients receive standard image baseline , include FDG-PET/CT plus MR brain imaging . Patients subsequently start protocol therapy MM-302 trastuzumab give day 1 every 21-day dosing cycle , recommend phase 2 dose 30 mg/m2 . Patients receive 64Cu-labeled MM-302 ( 3-5 mg/m2 doxorubicin ) three hour unlabeled dose MM-302 . Integrated MR/PET image brain whole body perform two time point follow 64Cu-labeled MM-302 administration : ( 1 ) within 3 hour ( +/- 1 hour ) label drug injection , ( 2 ) 24 hour ( +/- 6 hour ) post-injection . Patients continue receive subsequent dos unlabeled MM-302 plus trastuzumab every 3 week clinical radiographic disease progression ( either brain systemically ) unacceptable toxicity , whichever occur soonest . MR brain image FDG-PET/CT scan perform every 9 week monitor treatment response disease progression .</brief_summary>
	<brief_title>64-Cu Labeled Brain PET/MRI MM-302 Advanced HER2+ Cancers With Brain Mets</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm advanced solid tumor malignancy document HER2 overexpression gene amplification prior archival tumor tissue CLIAcertified laboratory New progressive brain metastasis least one metastasis measure ≥ 1 cm long diameter MR image Patients may extracranial metastatic disease require study entry Neurologically stable define ALL following : Stable decrease dose steroid anticonvulsant least 14 day prior study entry No clinically significant mass effect , midline shift , impend herniation baseline brain image No significant focal neurologic sign and/or symptom would necessitate radiation therapy surgical decompression judgment treat clinician Prior radiation therapy treatment brain metastasis complete least 4 week prior study entry Prior radiation therapy brain metastasis allow must least 4 week prior study entry follow image consistent pseudoprogression judgment treat clinician Patients must ambulatory ECOG performance status 0 1 . Adequate organ function , include absolute neutrophil count ( ANC ) ≥1500 cells/uL , hemoglobin ≥9.0 gm/dL , platelet ≥100,000 cells/uL , estimate creatinine clearance ≥50 mL/min ( Cockcroft Gault equation ) , bilirubin &lt; 1.5x ULN ( unless Gilbert 's suspect ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 1.5x ULN ( &lt; 3x ULN know liver metastasis ) . Ejection fraction assess MUGA echocardiogram &gt; 50 % Prior cumulative doxorubicin exposure &lt; 300 mg/m2 ( epirubicin equivalent ) Last dose prior systemic anticancer therapy administer least 5 halflives 4 week prior study entry , whichever short No contraindication MRI ( e.g . pacemaker , aneurysm clip , severe claustrophobia ) Patients sign studyspecific IRBapproved consent prior study entry . Patients must able willing consent undergo study procedure . Age ≥18 year old Prior treatment MM302 Patients class New York Heart Association ( NYHA ) CHF heart failure preserve ejection fraction ( HFPEF ) Patients history know coronary artery disease myocardial infarction within last 12 month Patients persistently uncontrolled hypertension ( systolic BP &gt; 160 mm Hg diastolic BP &gt; 100 mm Hg ) despite optimal medical therapy Patients know unstable angina pectoris Patients know history serious cardiac arrhythmia require treatment ( exception : control atrial fibrillation , paroxysmal supraventricular tachycardia ) Patients prolong QTc interval ( ≥ 450 m ) Patients previously discontinue trastuzumab due unacceptable cardiac toxicity Patients history LVEF decline 50 % prior trastuzumab/lapatinib HER2 direct therapy . Current dyspnea rest due complication advance malignancy disease require continuous oxygen therapy . Any serious and/or unstable preexist medical , psychiatric , medical condition could interfere subject 's safety , provision inform consent , compliance study procedure Presence leptomeningeal disease absence parenchymal brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>